Literature DB >> 23640485

Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation.

Shin-ichi Tanaka1, Yoshihiro Fukumoto, Kotaro Nochioka, Tatsuro Minami, Shun Kudo, Nobuyuki Shiba, Yoshimi Takai, Carol L Williams, James K Liao, Hiroaki Shimokawa.   

Abstract

OBJECTIVE: The pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) independent of cholesterol-lowering effects are thought to be mediated through inhibition of the Rho/Rho-kinase pathway. However, we have previously demonstrated that the pleiotropic effects of regular-dose statins are mediated mainly through inhibition of the Rac1 signaling pathway rather than the Rho/Rho-kinase pathway, although the molecular mechanisms of the selective inhibition of the Rac1 signaling pathway by regular-dose statins remain to be elucidated. In this study, we tested our hypothesis that small GTP-binding protein GDP dissociation stimulator (SmgGDS) plays a crucial role in the molecular mechanisms of the Rac1 signaling pathway inhibition by statins in endothelial cells. APPROACH AND
RESULTS: In cultured human umbilical venous endothelial cells, statins concentration-dependently increased SmgGDS expression and decreased nuclear Rac1. Statins also enhanced SmgGDS expression in mouse aorta. In control mice, the protective effects of statins against angiotensin II-induced medial thickening of coronary arteries and fibrosis were noted, whereas in SmgGDS-deficient mice, the protective effects of statins were absent. When SmgGDS was knocked down by its small interfering RNA in human umbilical venous endothelial cells, statins were no longer able to induce Rac1 degradation or inhibit angiotensin II-induced production of reactive oxygen species. Finally, in normal healthy volunteers, statins significantly increased SmgGDS expression with a significant negative correlation between SmgGDS expression and oxidative stress markers, whereas no correlation was noted with total or low-density lipoprotein-cholesterol.
CONCLUSIONS: These results indicate that statins exert their pleiotropic effects through SmgGDS upregulation with a resultant Rac1 degradation and reduced oxidative stress in animals and humans.

Entities:  

Keywords:  Rac; Rho; reactive oxygen species; small GTP-binding protein GDP dissociation stimulator; statins

Mesh:

Substances:

Year:  2013        PMID: 23640485      PMCID: PMC3863549          DOI: 10.1161/ATVBAHA.112.300922

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  46 in total

Review 1.  Pleiotropic effects of statin therapy: molecular mechanisms and clinical results.

Authors:  Chao-Yung Wang; Ping-Yen Liu; James K Liao
Journal:  Trends Mol Med       Date:  2008-01       Impact factor: 11.951

2.  Identification and characterization of the unique guanine nucleotide exchange factor, SmgGDS, in vascular smooth muscle cells.

Authors:  Rebecca Thill; William B Campbell; Carol L Williams
Journal:  J Cell Biochem       Date:  2008-08-01       Impact factor: 4.429

3.  SmgGDS is a guanine nucleotide exchange factor that specifically activates RhoA and RhoC.

Authors:  Brant Hamel; Elizabeth Monaghan-Benson; Rafael J Rojas; Brenda R S Temple; Daniel J Marston; Keith Burridge; John Sondek
Journal:  J Biol Chem       Date:  2011-01-17       Impact factor: 5.157

Review 4.  Pleiotropic effects of statins. - Basic research and clinical perspectives -.

Authors:  Qian Zhou; James K Liao
Journal:  Circ J       Date:  2010-04-15       Impact factor: 2.993

5.  Myocardial fibrosis in transforming growth factor beta(1)heterozygous mice.

Authors:  W W Brooks; C H Conrad
Journal:  J Mol Cell Cardiol       Date:  2000-02       Impact factor: 5.000

6.  Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.

Authors:  Ping-Yen Liu; Yen-Wen Liu; Li-Jen Lin; Jyh-Hong Chen; James K Liao
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

7.  Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.

Authors:  Shusuke Yagi; Ken-ichi Aihara; Yasumasa Ikeda; Yuka Sumitomo; Sumiko Yoshida; Takayuki Ise; Takashi Iwase; Kazue Ishikawa; Hiroyuki Azuma; Masashi Akaike; Toshio Matsumoto
Journal:  Circ Res       Date:  2007-10-25       Impact factor: 17.367

8.  Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors.

Authors:  Mamunur Rashid; Shunsuke Tawara; Yoshihiro Fukumoto; Minoru Seto; Kazuo Yano; Hiroaki Shimokawa
Journal:  Circ J       Date:  2008-12-08       Impact factor: 2.993

9.  Splice variants of SmgGDS control small GTPase prenylation and membrane localization.

Authors:  Tracy J Berg; Adam J Gastonguay; Ellen L Lorimer; John R Kuhnmuench; Rongshan Li; Alan P Fields; Carol L Williams
Journal:  J Biol Chem       Date:  2010-08-13       Impact factor: 5.157

10.  Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms.

Authors:  Kimio Satoh; Patrizia Nigro; Tetsuya Matoba; Michael R O'Dell; Zhaoqiang Cui; Xi Shi; Amy Mohan; Chen Yan; Jun-ichi Abe; Karl A Illig; Bradford C Berk
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

View more
  24 in total

1.  Structure-based analysis of the guanine nucleotide exchange factor SmgGDS reveals armadillo-repeat motifs and key regions for activity and GTPase binding.

Authors:  Hikaru Shimizu; Sachiko Toma-Fukai; Shinya Saijo; Nobutaka Shimizu; Kenji Kontani; Toshiaki Katada; Toshiyuki Shimizu
Journal:  J Biol Chem       Date:  2017-06-19       Impact factor: 5.157

Review 2.  Targeting Rac and Cdc42 GTPases in Cancer.

Authors:  María Del Mar Maldonado; Suranganie Dharmawardhane
Journal:  Cancer Res       Date:  2018-06-01       Impact factor: 12.701

Review 3.  Endothelial cell metabolism in normal and diseased vasculature.

Authors:  Guy Eelen; Pauline de Zeeuw; Michael Simons; Peter Carmeliet
Journal:  Circ Res       Date:  2015-03-27       Impact factor: 17.367

4.  Statins and Cognition in Parkinson's Disease.

Authors:  Benjamin L Deck; Jacqueline Rick; Sharon X Xie; Alice Chen-Plotkin; John E Duda; James F Morley; Lana M Chahine; Nabila Dahodwala; John Q Trojanowski; Daniel Weintraub
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

5.  CYP2J2 metabolites, epoxyeicosatrienoic acids, attenuate Ang II-induced cardiac fibrotic response by targeting Gα12/13.

Authors:  Zuowen He; Yong Yang; Zheng Wen; Chen Chen; Xizhen Xu; Yanfang Zhu; Yan Wang; Dao Wen Wang
Journal:  J Lipid Res       Date:  2017-05-29       Impact factor: 5.922

Review 6.  Pleiotropic Effects of Statins on the Cardiovascular System.

Authors:  Adam Oesterle; Ulrich Laufs; James K Liao
Journal:  Circ Res       Date:  2017-01-06       Impact factor: 17.367

7.  The effect and molecular mechanism of statins on the expression of human anti-coagulation genes.

Authors:  Sheng-Nan Chang; Cho-Kai Wu; Ling-Ping Lai; Fu-Tien Chiang; Juey-Jen Hwang; Chia-Ti Tsai
Journal:  Cell Mol Life Sci       Date:  2019-05-03       Impact factor: 9.261

8.  A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.

Authors:  Nicholas P Whitehead; Min Jeong Kim; Kenneth L Bible; Marvin E Adams; Stanley C Froehner
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-28       Impact factor: 11.205

Review 9.  Pleiotropic effects of statins: new therapeutic targets in drug design.

Authors:  Onkar Bedi; Veena Dhawan; P L Sharma; Puneet Kumar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-05       Impact factor: 3.000

Review 10.  Pleiotropic effects of statins on acute kidney injury: involvement of Krüppel-like factor 4.

Authors:  Tadashi Yoshida; Matsuhiko Hayashi
Journal:  Clin Exp Nephrol       Date:  2016-06-13       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.